BENEFIT
2016
Belatacept Evaluation of Nephroprotection and Efficacy as First-line Immunosuppression Trial
In 666 kidney-transplant recipients, belatacept improved 7-year patient and graft survival compared with ciclosporin.
Result
Efficacy: Death or graft loss at 7 yearsHR 0.57 (95% CI 0.35-0.95) · P = 0.02
Below 1 favours belatacept, above 1 favours ciclosporin.
Also reported: Mean eGFR ~70 vs ~45 mL/min.
- Subtopic
- Belatacept
- Design
- Phase 3 RCT, 7-year follow-up
- Relevance
- Important: one of several pillars.
- Source
- Vincenti F, et al. N Engl J Med. 2016;374(4):333-343.doi 10.1056/NEJMoa1506027
Discussion & critique
A CNI-free alternative with better kidney function; post-transplant lymphoproliferative risk restricts it to EBV-seropositive recipients.